Synmosa Biopharma Corporation

Total Valuation

Synmosa Biopharma Corporation carries a market capitalization of 16.46B, placing it among publicly traded companies globally. Its enterprise value stands at 17.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Synmosa Biopharma Corporation currently has 506.18M shares outstanding.

Valuation Ratios

Synmosa Biopharma Corporation trades at a trailing price-to-earnings ratio of 20.09. The price-to-sales ratio is 2.67, and the price-to-book ratio stands at 2.75.

Enterprise Valuation

On an enterprise value basis, Synmosa Biopharma Corporation trades at an EV/EBITDA multiple of 22.41 and an EV/FCF ratio of 23.54. The EV/Sales ratio of 2.82 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.41 provides insight into valuation relative to core operating earnings.

Financial Position

Synmosa Biopharma Corporation maintains a current ratio of 2.95, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.91, indicating elevated leverage, while an interest coverage ratio of 12.54 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Synmosa Biopharma Corporation posts a return on equity of 14.92 and a return on invested capital of 5.05.

Taxes

Over the trailing twelve months, Synmosa Biopharma Corporation has paid 181.22M in income taxes, reflecting an effective tax rate of 22.66.

Stock Price Statistics

Synmosa Biopharma Corporation's stock has gained approximately 6.66449% over the past 52 weeks. The 50-day moving average sits at 30.76, while the 200-day moving average is 32.05.

Income Statement

Over the trailing twelve months, Synmosa Biopharma Corporation generated 6.19B in revenue and converted that into 821.85M in net income, yielding earnings per share of 1.20. EBITDA reached 777.94M, while operating income came in at 777.94M.

Balance Sheet

Synmosa Biopharma Corporation holds 2.93B in cash and equivalents against 2.52B in total debt, resulting in a net debt position of 565.53M. Total book value stands at 6.00B, with working capital of 4.41B providing operational flexibility.

Cash Flow

Synmosa Biopharma Corporation produced 411.57M in operating cash flow over the past twelve months. After subtracting -281.13M in capital expenditures, free cash flow totaled 130.44M - equivalent to 0.26 per share.

Margins

Synmosa Biopharma Corporation operates with a gross margin of 43.28, reflecting its pricing power and cost economics. The operating margin of 12.57 and net profit margin of 13.28 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Synmosa Biopharma Corporation's most recent stock split took place on July 11, 2025 with a 1000:1099 split ratio.

Scores

Synmosa Biopharma Corporation posts an Altman Z-Score of 3.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.